A Pfizer spokesperson said in a statement that the company remains confident in Paxlovid’s clinical effectiveness ... the risk of severe COVID-19 outcomes.” At best, Paxlovid reduced their ...

Clinical trials moved quickly ... The result was a medicine called Paxlovid. But as with many things developed quickly, it was far from perfect. One of the big problems with this novel antiviral ...

The CDC described COVID-19 rebound cases as "a recurrence of symptoms or a new positive viral test after having tested negative" in guidance released in May Glenn Garner is a form writer-reporter ...

Last year, the influential Institute for Clinical and Economic Review (ICER) in the US said that a fair price for Paxlovid for commercial insurer payment would be between $563 and $906 per course.

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty.